Literature DB >> 16884786

Prevention of recurrent respiratory papillomatosis: role of HPV vaccination.

Gary L Freed1, Craig S Derkay.   

Abstract

Recurrent respiratory papillomatosis is a rare, but devastating, cause of airway lesions in children and adults. This disease is caused by human papilloma virus subtypes 6 and 11. At this time there are two vaccines in late stages of development seeking Food and Drug Administration (FDA) approval to prevent cervical cancer, which is also caused by human papilloma virus. One of these vaccines has been developed to stimulate immunity to the most common subtypes that cause cervical cancer but also includes those responsible for recurrent respiratory papillomatosis. With the possibility this could drastically reduce the incidence of RRP, the otolaryngology community should advocate for implementation of a vaccine program that provides effective prevention of HPV infection with subtypes 6 and 11.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884786     DOI: 10.1016/j.ijporl.2006.06.006

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  10 in total

1.  Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.

Authors:  Magdalena Chirilă; Sorana D Bolboacă
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05       Impact factor: 2.503

2.  Juvenile recurrent respiratory papillomatosis: A rare masquerade of asthma.

Authors:  W H Boo; P Rajan; S M Ching; P Y Lee
Journal:  Malays Fam Physician       Date:  2015-08-31

Review 3.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

Review 4.  Recurrent respiratory papillomatosis: an overview.

Authors:  Qingliang Xue; Haitao Wang; Jianxin Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-28       Impact factor: 3.267

Review 5.  Human papilloma virus (HPV) infection in children and adolescents.

Authors:  Ioannis N Mammas; George Sourvinos; Demetrios A Spandidos
Journal:  Eur J Pediatr       Date:  2008-12-03       Impact factor: 3.183

6.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

Review 7.  Emerging and re-emerging infectious disease in otorhinolaryngology.

Authors:  F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

8.  HPV Type 6 and 18 Coinfection in a Case of Adult-Onset Laryngeal Papillomatosis: Immunization with Gardasil.

Authors:  Virginia Fancello; Andrea Melis; Andrea Fausto Piana; Paolo Castiglia; Andrea Cossu; Giovanni Sotgiu; Corrado Bozzo; Emma Victoria King; Francesco Meloni
Journal:  Case Rep Otolaryngol       Date:  2015-11-29

9.  The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia

Authors:  Soewarta Kosen; Andrijono Andrijono; Dwiana Ocviyanti; Wresti Indriatmi
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

10.  HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis.

Authors:  Paul Stefan Mauz; Fabian Axel Schäfer; Thomas Iftner; Phillipp Gonser
Journal:  BMC Infect Dis       Date:  2018-07-24       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.